|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Hemorrhage and endotoxemia are important risk factors for
the development of acute lung injury. Interleukin (IL)-18 is a
recently described cytokine released in its mature, active form
after pro-IL-18 is cleaved by the IL-1 converting enzyme (ICE).
IL-18 has multiple immunomodulating properties, including
induction of interferon-
(IFN-
), IL-1
, tumor necrosis factor-
, and intercellular adhesion molecule-1. To examine the
possible involvement of IL-18 in acute lung injury, we examined its expression, as well as that of IFN-
, IL-12, and ICE, using murine hemorrhage or endotoxemia models. The
amounts of IL-18 messenger RNA (mRNA) increased in the
lung after hemorrhage or endotoxemia. However, only endotoxemia was associated with elevations in lung and plasma
concentrations of IL-18 protein. ICE expression was increased
in the lungs after endotoxemia but not after hemorrhage. Although IFN-
expression increased in the lungs after hemorrhage or endotoxemia, elevations in lung IL-12 mRNA levels
were found only after endotoxemia. These results indicate
that hemorrhage and endotoxemia induce different patterns
of immunomodulatory cytokine expression in the lungs. In
particular, differences in the expression of ICE after hemorrhage or endotoxemia may affect generation of the active
forms of downstream cytokines, including IL-18. IFN-
expression in the lungs after hemorrhage appears to occur through
a pathway independent of IL-12 and IL-18. IL-18 may play a
role in modulating the development of acute lung injury after
endotoxemia but not after hemorrhage.
| |
Introduction |
|---|
|
|
|---|
Acute lung injury (ALI) and its most severe form, acute
respiratory distress syndrome (ARDS), are important clinical entities affecting approximately 150,000 patients in the
United States per year (1, 2). Infection and blood loss are
two major, well-described etiologies predisposing to the
development of ALI (1, 2). Endotoxemia or hemorrhage
induces increases in the expression of proinflammatory cytokines, including tumor necrosis factor (TNF)-
, interleukin (IL)-1
, IL-1
, interferon (IFN)-
, and macrophage
inflammatory peptide-2 in murine lung cells (3), and increased levels of TNF-
and IFN-
are present in bronchoalveolar lavage fluid (BALF) after hemorrhage (8).
These experimental findings correlate with those from
clinical studies where elevated levels of immunoregulatory
cytokines, including IL-1
, IL-8, TNF-
, and IL-6, are
present in the plasma and BALF of patients with ARDS
compared with control patients receiving mechanical ventilation (9). Recently, the proinflammatory activity of
BALF was shown to be significantly greater than that of
plasma in patients with ARDS, suggesting that the lung is
an active, local site of inflammation in this setting (13, 14).
IL-18, also called interferon gamma inducing factor, is a
recently described cytokine initially isolated from hepatic
Kupffer cells (15). IL-18 is constitutively expressed in
lung, skin, skeletal muscle, kidney, and pancreas (18, 19). In
in vitro studies, IL-18 increases IL-1
, TNF-
, IL-8, IL-2,
and granulocyte macrophage colony-stimulating factor
(GM-CSF) release (20), decreases IL-10 release (20), upregulates intercellular adhesion molecule-1 expression (23),
enhances T-cell proliferation (20, 24), increases natural killer
cell activity through Fas ligand-mediated pathways (25),
and can decrease angiogenesis in tumor models (28).
Similar to pro-IL-1
, pro-IL-18 lacks a signal sequence
and requires cleavage to its mature and active form, which
is then secreted (29, 30). The interleukin-1 converting enzyme (ICE) is the predominant enzyme responsible for
the cleavage of pro-IL-18 to mature IL-18 (29).
The importance of IL-18 in the underlying pathophysiologic response to endotoxemia, an important risk factor for
the development of ALI, was recently illustrated in IL-18 receptor knockout mice that were resistant to the effects of endotoxemia compared with wild-type control mice (27). However, little is known concerning the kinetics of expression of
IL-18 in the lungs after endotoxemia or other inflammatory
insults, such as blood loss, that are associated with the development of ALI. We therefore investigated the effects of endotoxemia and hemorrhage on IL-18 and ICE expression in
the lungs. Because IL-12 and IL-18 have overlapping properties of inducing IFN-
expression (32), we also examined the ability of endotoxemia or hemorrhage to modulate
pulmonary expression of IL-12 and IFN-
.
| |
Materials and Methods |
|---|
|
|
|---|
Animals
Male BALB/c mice, ages 8 to 12 wk, were obtained from Harlen Sprague Dawley (Indianapolis, IN) and housed in the University of Colorado Health Sciences Center animal care facility. Mice were kept on a 12-h light/dark cycle with free access to food and water.
Endotoxemia or Hemorrhage Models
The endotoxemia and hemorrhage models used in these experiments have been described previously by our laboratory (3, 4, 6- 8). Both are associated with onset of ALI within 72 h as evidenced by pulmonary neutrophil infiltration, interstitial pulmonary edema, and proteinaceous alveolar exudate (3, 7, 37, 38).
For endotoxemia, mice were injected intraperitoneally with lipopolysaccharide (Escherichia coli 0111:B4; Sigma, St. Louis, MO) at the dose of 25 mg/kg in 0.2 ml phosphate-buffered saline (PBS). Control mice received 0.2 ml PBS intraperitoneally. Hemorrhage was performed by removal of 30% of the calculated total blood volume (0.55 ml for a 20-g mouse) by cardiac puncture over 60 s under methoxyflurane anesthesia. With this method, overall mortality is < 12%, with no evidence of bleeding into the pericardial space, hemothorax, or lung or cardiac contusion (3, 4, 6). Control animals underwent cardiac puncture under methoxyflurane anesthesia without blood removal.
Lung Isolation and BALF Collection
At predetermined time points, mice were exsanguinated by cardiac puncture under methoxyflurane anesthesia. The blood was drawn into a heparinized syringe (5 U heparin), then centrifuged at 2,500 rpm for 10 min for plasma collection. After death, the chest cavity was opened, the right ventricle flushed with 3 to 5 ml of PBS at 4°C, and the lungs removed with avoidance of the peritracheal lymph nodes (3, 5, 8). The lungs were then snap-frozen in liquid nitrogen with the right lung used for RNA extraction and the left lung used for protein analysis.
Semiquantitative Reverse Transcriptase/Polymerase Chain Reaction
The techniques used for semiquantitative reverse transcriptase/ polymerase chain reaction (RT-PCR) have been previously described by our laboratory (3). Total RNA was isolated from the right lung by phenol-chloroform extraction after homogenization in 2 ml of 4 M guanidine thiocyanate/5 mM sodium citrate/0.5% sarcosyl and 0.1 M 2-mercaptoethanol. Complementary DNA (cDNA) was then synthesized from 1 µg total RNA using Maloney murine leukemia virus reverse transcriptase and random hexamer oligonucleotides as previously described by our laboratory (3, 4, 6).
Semiquantitative PCR for IL-18, IFN-
, IL-12, and ICE was
performed using 5 µl of the cDNA mixture under the following
cycle conditions (except for ICE): initial 2 min 94°C denaturation
step followed by 30 to 38 cycles of 60 s, 94°C denaturation; 60 s, 55 to 65°C annealing (depending on cytokine primers); and 60 s, 72°C extension. A final 4-min extension at 72°C was then performed. For ICE, the cycle conditions were an initial 1 min 95°C
denaturation step followed by 38 to 40 cycles of 30 s, 94°C denaturation; 30 s, 54°C annealing; and 60 s, 72°C extension. This was
followed by a 5-min 72°C final extension step. PCR products
were visualized by electrophoresis on 1.6% agarose gels with
ethidium bromide staining. Cycle number was adjusted so that
the PCR products were between barely visible and below saturation. The housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (G3PDH) and hypoxanthine phospho-ribosyl transferase (HPRT) were used as controls. Analysis of the gel was
done by densitometry (ImageStore 5000; UVP, San Gabriel, CA)
with relative absorbance determined by comparison of the density of the PCR product of the cytokine of interest to the housekeeping gene.
Measurement of IL-18 Protein
For assessment of IL-18 protein levels, an electrochemiluminescence (ECL) assay was used. The techniques used for the ECL assay have been described previously (22). Briefly, the left lung
was homogenized in lysis buffer containing N-2-hydroxyethylpiperazine-N'-ethane sulfonic acid 10 mM, NaCl 150 mM, Igepal 1%
vol/vol, ethylenediaminetetraacetic acid 1 mM, leupeptin 1 µg/ml,
phenylmethylsulfonyl fluoride 100 µg/ml, aprotinin 1 µg/ml, pepstatin 1 µg/ml, and soybean trypsin inhibitor 1 µg/ml; centrifuged
at 2,500 rpm for 10 min; and the supernatant was then removed,
aliquoted, and kept at
80°C until analyzed for IL-18 levels. Antibodies used were an affinity-purified, antimurine IL-18 polyclonal antibody (R&D Systems, Minneapolis, MN) that was
labeled with bioten (Igen Inc., Gaithersburg, MD) as per manufacturer's protocol, and a monoclonal, antimurine IL-18 antibody
(R&D Systems) labeled with ruthenium (II) trisbipyride chelate
(Igen) as per the manufacturer's instructions. The biotinylated antibody was diluted to a final concentration of 0.5 µg/ml in PBS
(pH 7.4) containing 0.25% bovine serum albumin, 0.5% Tween-20, and 0.01% azide (ECL buffer). In each assay tube, 25 µl of
the above biotinylated anti-IL-18 antibody was incubated at
room temperature with 25 µl of a 1-mg/ml solution of streptavidin-coated paramagnetic beads (Dynal Corp., Lake Success, NY)
diluted in ECL buffer for 30 min with mixing by vigorous shaking. To each assay tube, 25 µl of sample or standard concentrations of recombinant murine IL-18 (Pepro-Tech Inc., Rocky Hill,
NJ) were added, followed by 25 µl of the ruthenylated antibody
(final concentration 1 mg/ml, diluted in ECL buffer), and incubated overnight at room temperature with shaking. The reaction
was quenched with 200 µl of PBS per tube and the amount of
chemiluminescence was determined using an Origen 1.5 analyzer
(Igen Inc.). A standard curve was constructed using recombinant
IL-18 (Pepro-Tech, Inc.). The IL-18 ECL detects both pro- and
mature IL-18 with a sensitivity of 20 pg/ml.
Statistical Analysis
Groups of 5 to 8 mice were used for each time point. For each experimental condition, groups of control, unmanipulated animals were included. Data are presented as mean normalized to controls ± standard error of the mean (SEM) for each experimental group. Groups were compared using one-way analysis of variance and the Tukey-Kramer multiple comparison tests for differences between groups. A P value < 0.05 was considered to be statistically significant.
| |
Results |
|---|
|
|
|---|
IL-18 Expression Is Increased in the Lung after Endotoxemia or Hemorrhage
As reported previously (18, 19), we found that IL-18 messenger RNA (mRNA) is constitutively expressed in the lung (Figure 1). As early as 1 h after endotoxemia, there was increased expression of IL-18 mRNA in the lungs, followed by a decrease to below baseline levels of expression 4 h after endotoxin administration. No detectable IL-18 mRNA, even with 40 cycles of PCR, could be found 8 h after endotoxemia (Figures 1A and 1B).
|
Amounts of IL-18 mRNA were increased in the lung after hemorrhage. As shown in Figure 1, IL-18 expression in the lungs increased more slowly after hemorrhage than after endotoxemia, with peak in IL-18 mRNA levels being present 4 h after hemorrhage with return to below baseline levels 4 h later.
IL-18 Protein Levels Are Increased in the Lung and Plasma after Endotoxemia but Not after Hemorrhage
Because alteration in IL-18 mRNA levels may not necessarily correlate with changes in protein, we investigated IL-18 protein in the lung and plasma of mice either given endotoxin or hemorrhaged. Significant increases in IL-18 protein were present in the lungs 1 h after endotoxemia (Figure 2A). Pulmonary IL-18 levels remained significantly elevated, compared with those present in unmanipulated mice, 4 h after endotoxemia, and then returned to baseline levels 8 h after endotoxin administration. In contrast to the increased levels of IL-18 present in the lung after endotoxemia, we did not find any significant alterations in IL-18 protein in the lung during the 8-h period after hemorrhage. In bronchoalveolar lavage, IL-18 was undetectable in control, unmanipulated mice and at all time points after endotoxemia or hemorrhage (data not shown).
|
In plasma, low levels of IL-18 were found at baseline. Increases in plasma IL-18 occurred as early as 1 h after endotoxin administration, reached statistical significance 4 h after endotoxemia, and then returned to baseline 4 h later (Figure 2B). In contrast to endotoxemia, hemorrhage did not produce any statistically significant changes in plasma IL-18 levels (data not shown).
IFN-
Expression Is Increased in the Lung after
Endotoxemia or Hemorrhage
IFN-
mRNA levels rose after endotoxin injection, with significant increases, compared with baseline, being present 4 and 8 h after endotoxin administration (Figure 3A). The
expression of IFN-
mRNA in the lung also increased after hemorrhage, but with kinetics different from those
seen after endotoxin administration. The peak in expression of IFN-
mRNA occurred 4 h after hemorrhage and
was of short duration, with a return to below baseline 8 h after blood loss (Figure 3B).
|
Expression of IL-12 mRNA Is Increased in the Lung after Endotoxemia but Not after Hemorrhage
IL-12 induces IFN-
expression both alone and in synergy
with IL-18, in part by upregulating IL-18 receptors (32).
In the present experiments, there was a rapid, but transient, increase in the expression of IL-12 mRNA in the
lung after endotoxin administration (Figure 4). IL-12
mRNA levels were significantly greater than those present
in the lungs of control, unmanipulated mice 1 h after endotoxin administration. By 4 h after endotoxin administration, IL-12 expression was similar to baseline. After hemorrhage, the only significant alteration in IL-12 expression
was a decrease 8 h after blood loss.
|
ICE mRNA Expression Is Increased in the Lung after Endotoxemia but Not after Hemorrhage
Because ICE is important in cleaving pro-IL-18 to mature IL-18 (29), we investigated its expression in the lung after endotoxemia or hemorrhage. ICE mRNA was constitutively present in the lung (Figure 5), and then increased 4 h after endotoxemia, before returning to baseline levels 8 h after endotoxin administration (Figure 5). After hemorrhage, there was no alteration in the expression of ICE mRNA in the lung at any of the time points investigated.
|
| |
Discussion |
|---|
|
|
|---|
In these experiments, we found that endotoxemia and hemorrhage produce rapid increases in the expression of IL-18 mRNA in the lung, present between 1 and 4 h, respectively, after each of these conditions. The kinetics of IL-18 mRNA expression in the lung after endotoxemia or hemorrhage are consistent with those reported in previous in vitro studies (39, 40). In keratinocytes exposed to contact allergens, IL-18 mRNA levels increased between 4 and 6 h (39). When human peripheral blood mononuclear cells are exposed to endotoxin, IL-18 mRNA levels peak between 2 and 6 h (40). In the only other in vivo study investigating IL-18 after endotoxemia, an increase in IL-18 mRNA levels in murine splenocytes was found within 2 h after endotoxin administration (41). In that study, pulmonary expression of IL-18 was not examined (41).
In addition to inducing increases in IL-18 mRNA expression, we found that endotoxin administration was followed by increased IL-18 protein in the lung and plasma. The elevations in lung and plasma IL-18 protein levels were of short duration, occurring between 1 and 4 h after endotoxemia, and suggest that IL-18 may be active in the lung early in the proinflammatory response. Our findings of increased IL-18 plasma levels after endotoxemia are similar to the kinetics of IL-18 protein levels seen in an earlier in vivo study (15) where IL-18 serum levels peaked 2 h after endotoxemia, with a gradual return to baseline over the next 4 h.
We did not find an increase in IL-18 protein levels in the
lung or plasma after hemorrhage, suggesting that there are
differences in the post-transcriptional regulation and therefore probable importance of IL-18 in these two models of
ALI. The explanation for the lack of an increase in IL-18
levels after hemorrhage, in the face of elevated IL-18
mRNA expression, may be related to differences in ICE
activity after endotoxemia or hemorrhage. We found that
ICE expression in the lung was increased after endotoxemia, but not after hemorrhage. Unlike pro-IL-1
where
proteases other than ICE are able to generate mature IL-1
, ICE is currently the only known protease able to cleave
pro-IL-1
into its mature and active form (29).
Endotoxin-associated increases in IFN-
mRNA levels
occurred after the peak in IL-18 mRNA expression and simultaneously with the peak in IL-18 plasma levels. This
suggests that IL-18 may be responsible for the enhanced expression of IFN-
in the lung after endotoxemia. Previous
studies showed that IL-18 occupies an important role in inducing IFN-
expression after endotoxemia (15, 16, 27, 31).
In particular, IFN-
expression was markedly reduced both
in ICE and in IL-18 knockout mice compared with wild-type control mice after endotoxin administration (27, 31).
Because IL-18 protein levels do not increase in the
lungs after hemorrhage, other factors would appear to be
responsible for inducing IFN-
expression in this setting.
The importance of IL-18 in inducing IFN-
expression after inflammatory insults other than endotoxemia has not
been well characterized. A recent study showed that IL-18
is important for IFN-
expression after zymosan exposure
(31). However, there are no previous studies that have investigated interrelationships between IL-18 and IFN-
after hemorrhage.
IL-2, TNF-
, and IL-12 can increase IFN-
expression
(15, 33, 42). IL-12, although considered a weaker inducer of IFN-
than IL-18, increases IFN-
expression,
both primarily and in synergy with IL-18 (32). In our
study, we failed to find an increase in IL-12 mRNA levels
in the lung after hemorrhage, indicating that IL-12 was unlikely to have been responsible for the observed effects on
IFN-
. In previous studies (4), we found that hemorrhage resulted in upregulation of TNF-
, but not of IL-2, in the
lungs, suggesting that TNF-
, but not IL-2, may play a role
in modulating IFN-
expression after blood loss. Additionally, signaling through the p38 mitogen-activated protein (MAP) kinase pathway has previously been shown to
upregulate IFN-
expression in vitro (43). This suggests
that other mediators, such as IL-1
, IL-3, and GM-CSF, which use the p38 MAP kinase signaling pathway, may be
involved in the induction of IFN-
expression in the lung
after hemorrhage (43).
| |
Footnotes |
|---|
Address correspondence to: Edward Abraham, M.D., Division of Pulmonary and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box C-272, Denver, CO 80262. E-mail: Edward.Abraham{at}UCHSC.edu
(Received in original form June 15, 1999 and in revised form January 6, 2000).
Abbreviations: acute lung injury, ALI; acute respiratory distress syndrome, ARDS; bronchoalveolar lavage fluid, BALF; electrochemiluminescence, ECL; glyceraldehyde-3-phosphate dehydrogenase, G3PDH; hypoxanthine phospho-ribosyl transferase, HPRT; interleukin-1 converting enzyme, ICE; interferon, IFN; interleukin, IL; lipopolysaccharide, LPS; messenger RNA, mRNA; phosphate-buffered saline, PBS; reverse transcriptase/polymerase chain reaction, RT-PCR; standard error of the mean, SEM; tumor necrosis factor, TNF.Acknowledgments: This study was supported in part by National Institutes of Health grant HL 50284 (E.A.) and Glaxo Wellcome Pulmonary Fellowship Award (P.G.A.).
| |
References |
|---|
|
|
|---|
1. Hudson, L., J. Milberg, D. Anardi, and R. Maunder. 1995. Clinical risk for development of acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 151: 293-301 [Abstract].
2. Garber, B., P. Hebert, J. D. Yelle, R. Hodder, and J. McGowan. 1996. Adult respiratory distress syndrome: a systemic overview of incidence and risk factors. Crit. Care Med. 24: 687-695 [Medline].
3. Shenkar, R., W. Coulson, and E. Abraham. 1994. Hemorrhage and resuscitation induce alterations in cytokine expression and the development of acute lung injury. Am. J. Respir. Cell Mol. Biol. 10: 290-297 [Abstract].
4. Shenkar, R., and E. Abraham. 1993. Effects of hemorrhage on cytokine gene transcription. Lymphokine Cytokine Res. 12: 237-247 [Medline].
5.
Abraham, E.,
D. Kaneko, and
R. Shenkar.
1999.
Effects of endogenous and
exogenous catecholamine on LPS-induced neutrophil trafficking and activation.
Am. J. Physiol.
276:
L1-L8
6. Tulzo, Y., R. Shenkar, D. Kaneko, P. Mione, G. Fantuzzi, C. Dinarello, and E. Abraham. 1997. Hemorrhage increases cytokine expression in lung mononuclear cells in mice. J. Clin. Invest. 99: 1516-1524 [Medline].
7.
Abraham, E.,
S. Bursten,
R. Shenkar,
J. Albee,
R. Tuder,
P. Woodson,
D. Guidot,
G. Rice,
J. Singer, and
J. Repine.
1995.
Phosphatidic acid signaling
mediates lung cytokine expression and lung inflammatory injury after
hemorrhage in mice.
J. Exp. Med.
181:
569-575
8. Abraham, E., W. F. Coulson, M. D. Schwartz, and J. Albee. 1994. Effects of therapy with soluble tumor necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following hemorrhage and resuscitation. Clin. Exp. Immunol. 98: 29-34 [Medline].
9. Millar, A. B., M. Singer, A. Meager, N. M. Foley, N. Johnson, and G. A. W. Rook. 1989. Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 2: 712-713 [Medline].
10.
Chollet-Martin, S.,
P. Montravers,
C. Gibert,
C. Elbim,
J. M. Desmonts,
J. Y. Fagon, and
M. A. Gougerot-Pocidalo.
1993.
High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and
adult respiratory distress syndrome.
Infect. Immun.
61:
4553-4559
11. Miller, E. J., A. B. Cohen, S. Nagoa, D. Griffith, R. J. Maunder, T. R. Martin, J. P. Weiner-Kronish, M. Sticherling, E. Christophers, and M. A. Matthay. 1992. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am. Rev. Respir. Dis. 146: 427-432 [Medline].
12. Chollet-Martin, S., B. Jourdain, C. Gibert, C. Elbim, J. Chastre, and M. A. Gougerot-Pocidalo. 1996. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am. J. Respir. Crit. Care Med. 153: 594-601 .
13. Pugin, J., B. Ricou, K. Steinberg, P. Suter, and T. Martin. 1996. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am. J. Respir. Crit. Care Med. 153: 1850-1856 [Abstract].
14. Pugin, J., G. Verbhese, M. C. Widmer, and M. Matthay. 1999. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit. Care Med. 27: 304-312 [Medline].
15.
Nakamura, K.,
H. Okamura,
M. Wada,
K. Nagata, and
T. Tamura.
1989.
Endotoxin-induced serum factor that stimulates gamma interferon production.
Infect. Immun.
57:
590-595
16.
Nakamura, K.,
H. Okamura,
K. Nagata,
T. Komatsu, and
T. Tamura.
1993.
Purification of a factor which provides a costimulatory signal for gamma
interferon production.
Infect. Immun.
61:
64-70
17. Okamura, H., K. Nagata, T. Komatsu, T. Tanimoto, Y. Nukuta, F. Tanabe, K. Akita, K. Torigoe, T. Okura, S. Fukuda, and M. Kurimoto. 1995. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect. Immun. 63: 3966-3972 [Abstract].
18.
Ushio, S.,
M. Namba,
T. Okura,
K. Hattori,
Y. Nukuda,
K. Akita,
F. Tanabe,
K. Konishi,
M. Micallef,
M. Fujii,
K. Torigoe,
T. Tanimoto,
S. Fukuda,
M. Ikeda,
H. Okamura, and
M. Kurimoto.
1996.
Cloning of the cDNA for human IFN-
-inducing factor, expression in Escherichia coli, and studies on
the biologic activities of the protein.
J. Immunol.
156:
4274-4279
[Abstract].
19.
Tone, M.,
S. Thompson,
Y. Tone,
P. Fairchild, and
H. Waldman.
1997.
Regulation of IL-18 (IFN-
-inducing factor) gene expression.
J. Immunol.
159:
6156-6163
[Abstract].
20.
Micallef, M.,
T. Ohtsuki,
K. Kohno,
F. Tanabe,
S. Ushio,
M. Namba,
T. Tanimoto,
K. Torigoe,
M. Fujii,
M. Ikeda,
S. Fukuda, and
M. Kurimoto.
1996.
Interferon-
-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-
production.
Eur. J. Immunol.
26:
1647-1651
[Medline].
21. Horwood, N. J., N. Udagawa, J. Elliott, D. Grail, H. Okumura, M. Kurimoto, A. R. Dunn, T. Martin, and M. T. Gillespie. 1998. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 101: 595-603 [Medline].
22.
Puren, A.,
G. Fantuzzi,
Y. Gu,
M. Su, and
C. Dinarello.
1998.
Interleukin-18
(IFN-
-inducing factor) induces IL-8 and IL-1
via TNF-
production
from non-CD14+ human blood mononuclear cells.
J. Clin. Invest.
101:
711-721
[Medline].
23.
Kohka, H.,
T. Yoshino,
H. Iwagaki,
I. Sakuma,
T. Tanimoto,
Y. Matsuo,
M. Kurimoto,
K. Orita,
T. Akagi, and
N. Tanaka.
1998.
Interleukin-18/interferon-
-inducing factor, a novel cytokine, upregulates ICAM-1 (CD45)
expression in KG-1 cells.
J. Leukoc. Biol.
64:
519-527
[Abstract].
24.
Xu, D.,
W. Chan,
B. Leung,
D. Hunter,
K. Schulz,
R. Carter,
I. McInnes,
J. Robinson, and
F. Liew.
1998.
Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells.
J. Exp. Med.
188:
1485-1492
25.
Tsutsui, H.,
K. Nakanishi,
K. Matsui,
K. Higashino,
H. Okamura,
Y. Miyazawa, and
K. Kaneda.
1996.
IFN-
-inducing factor upregulates Fas
ligand-mediated cytotoxic activity of murine natural killer cell clones.
J.
Immunol.
157:
3967-3973
[Abstract].
26.
Micallef, M.,
T. Tanimoto,
K. Kohno,
M. Ikeda, and
M. Kurimoto.
1997.
Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with
Meth A sarcoma.
Cancer Res.
57:
4557-4563
27. Takeda, K., H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okumura, K. Nakanishi, and S. Akira. 1998. Defective NK cell activity and TH1 response in IL-18 deficient mice. Immunity 8: 383-390 [Medline].
28. Coughin, C., K. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. Chang, C. Hunter, J. Fox, G. Trinchieri, and W. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101: 1441-1452 [Medline].
29.
Gu, Y.,
K. Kuida,
H. Tsutsui,
G. Ku,
K. Hsiao,
M. Fleming,
N. Hayashi,
K. Higashino,
H. Okamara,
K. Nakanaishi,
M. Kurimoto,
T. Tanimoto,
R. Flavell,
V. Sato,
M. Harding,
D. Livingston, and
M. Su.
1997.
Activation of
interferon-
-inducing factor mediated by interleukin-1
converting enzyme.
Science
275:
206-209
30.
Ghayur, T.,
S. Banarjee,
M. Hugunin,
D. Butler,
L. Herzog,
A. Carter,
L. Quintal,
L. Sekut,
R. Talanian,
M. Paskind,
W. Wong,
R. Kamen,
D. Tracey, and
H. Allen.
1997.
Caspase-1 processes IFN-
-inducing factor
and regulates LPS-induced IFN-
production.
Nature
386:
619-623
[Medline].
31.
Fantuzzi, G.,
A. Puren,
M. Harding,
D. Livingston, and
C. Dinarello.
1998.
Interleukin-18 regulation of interferon
production and cell proliferation
as shown in interleukin-1
-converting enzyme (caspase-1) deficient mice.
Blood
91:
2118-2125
32.
Kobayashi, M.,
L. Fitz,
M. Ryan,
R. Hewick,
S. Clark,
S. Chan,
R. Loudon,
F. Sherman,
B. Perussia, and
G. Trinchieri.
1989.
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with
multiple biologic effects on human lymphocytes.
J. Exp. Med.
170:
827-845
33.
Heinzel, F.,
R. Rerko,
P. Ling,
J. Hakimi, and
D. Schoenhaut.
1994.
Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis
of gamma interferon.
Infect. Immun.
62:
4244-4249
34.
Wysocka, M.,
M. Kubin,
I. Viera,
L. Ozmen,
G. Garotta,
P. Scott, and
G. Trinchieri.
1995.
Interleukin-12 is required for interferon
production and
lethality in lipopolysaccharide-induced shock in mice.
Eur. J. Immunol.
25:
672-676
[Medline].
35.
Ahn, H. J.,
S. Maruo,
M. Tomura,
J. Mu,
T. Hamaoka,
K. Nakanishi,
S. Clark,
M. Kurimoto,
H. Pkamura, and
H. Fujiwara.
1997.
A mechanism
underlying synergy between IL-12 and IFN-
-inducing factor in enhanced
production of IFN-
.
J. Immunol.
159:
2125-2131
36.
Munder, M.,
M. Mallo,
K. Eichmann, and
M. Modolell.
1998.
Murine macrophages secrete interferon
upon combined stimulation with interleukin
(IL)-12 and IL-18: a novel pathway of autocrine macrophage activation.
J.
Exp. Med.
187:
2103-2108
37.
Nathans, A.,
R. Bitar,
C. Davreux,
M. Bujard,
J. Marshall,
A. Dackiw,
R. Watson, and
O. Rotstein.
1997.
Pyrrolidine dithiocarbamate attentuates
endotoxin-induced acute lung injury.
Am. J. Respir. Cell Mol. Biol.
17:
608-616
38. Kelley, D., A. Lichtenstein, J. Wang, A. Taylor, and S. Dubinett. 1994. Corticotropin-releasing factor reduces lipopolysaccharide-induced pulmonary vascular leak. Immunopharmacol. Immunotoxicol. 16: 139-148 [Medline].
39.
Stoll, S.,
G. Muller,
M. Kurimoto,
J. Saloga,
T. Tanimoto,
H. Yamauchi,
H. Okamura,
J. Knop, and
A. Enk.
1997.
Production of IL-18 (IFN-
-inducing factor) messenger RNA and functional protein by murine keratinocytes.
J. Immunol.
159:
298-302
[Abstract].
40. Marshall, J., M. Adte-Amezega, S. Chehimi, M. Murphy, H. Olsen, and G. Trinchieri. 1999. Regulation of human IL-18 mRNA expression. Clin. Immunol. 90: 15-21 [Medline].
41.
Puren, A.,
G. Fantuzzi, and
C. Dinarello.
1999.
Gene expression, synthesis,
and secretion of interleukin 18 and interleukin 1
are differently regulated
in human blood mononuclear cells and mouse spleen cells.
Proc. Natl.
Acad. Sci. USA
96:
2256-2261
42.
Tripp, C.,
S. Wolf, and
E. Unanue.
1993.
Interleukin 12 and tumor necrosis
factor
are costimulators of interferon
production by natural killer cells in
severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.
Proc. Natl. Acad. Sci. USA
90:
3725-3729
43.
Rincon, M.,
H. Ensleen,
J. Raingeaud,
M. Recht,
T. Zapton,
M. Su,
L. Penix,
R. Davis, and
R. Flavell.
1998.
Interferon-
expression by Th1 effector cells mediated by the p38 MAP kinase signaling pathway.
EMBO J.
17:
2817-2829
[Medline].
This article has been cited by other articles:
![]() |
E. Abraham Computational Design of Variant TNF Molecules: A Novel Methodology for Inhibition of Proinflammatory Cascades Sci. Signal., November 11, 2003; 2003(208): pe51 - pe51. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Weijer, M. E. Sewnath, A. F. de Vos, S. Florquin, K. van der Sluis, D. J. Gouma, K. Takeda, S. Akira, and T. van der Poll Interleukin-18 Facilitates the Early Antimicrobial Host Response to Escherichia coli Peritonitis Infect. Immun., October 1, 2003; 71(10): 5488 - 5497. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Schultz, S. Knapp, S. Florquin, J. Pater, K. Takeda, S. Akira, and T. van der Poll Interleukin-18 Impairs the Pulmonary Host Response to Pseudomonas aeruginosa Infect. Immun., April 1, 2003; 71(4): 1630 - 1634. [Abstract] [Full Text] |
||||
![]() |
T. H. Wyman, C. A. Dinarello, A. Banerjee, F. Gamboni-Robertson, A. A. Hiester, K. M. England, M. Kelher, and C. C. Silliman Physiological levels of interleukin-18 stimulate multiple neutrophil functions through p38 MAP kinase activation J. Leukoc. Biol., August 1, 2002; 72(2): 401 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Raeburn, C. A. Dinarello, M. A. Zimmerman, C. M. Calkins, B. J. Pomerantz, R. C. McIntyre Jr., A. H. Harken, and X. Meng Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H650 - H657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.D. Aitchison, H.E. Orr, P.A. Flecknell, J.A. Kirby, and J.H. Dark Functional assessment of non-heart-beating donor lungs: prediction of post-transplant function Eur. J. Cardiothorac. Surg., July 1, 2001; 20(1): 187 - 194. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |